BCM
ALLO icon

Bourgeon Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Bourgeon Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.6K Buy
+45,000
New +$98.8K 0.01% 104
2025
Q3 		– Sell
-110,000
Closed -$124K – 111
2025
Q2 		$124K Buy
+110,000
New +$146K 0.02% 107
2025
Q1 		– Sell
-118,700
Closed -$253K – 107
2024
Q4 		$253K Sell
118,700
-23,880
-17% -$58.9K 0.05% 110
2024
Q3 		$399K Buy
142,580
+10,125
+8% +$27K 0.08% 84
2024
Q2 		$309K Buy
132,455
+75,255
+132% +$222K 0.06% 94
2024
Q1 		$256K Buy
57,200
+6,500
+13% +$27.1K 0.05% 101
2023
Q4 		$163K Sell
50,700
-11,000
-18% -$31.2K 0.04% 109
2023
Q3 		$196K Sell
61,700
-5,250
-8% -$23K 0.05% 95
2023
Q2 		$333K Buy
66,950
+39,000
+140% +$211K 0.08% 88
2023
Q1 		$138K Hold
27,950
– – 0.03% 104
2022
Q4 		$176K Buy
27,950
+17,000
+155% +$157K 0.04% 102
2022
Q3 		$118K Sell
10,950
-21,050
-66% -$286K 0.03% 104
2022
Q2 		$365K Buy
32,000
+5,500
+21% +$48.8K 0.1% 76
2022
Q1 		$241K Buy
26,500
+20,000
+308% +$208K 0.05% 90
2021
Q4 		$97K Sell
6,500
-25,225
-80% -$445K 0.02% 124
2021
Q3 		$815K Sell
31,725
-1,575
-5% -$37.4K 0.17% 67
2021
Q2 		$868K Buy
+33,300
New +$950K 0.19% 75
2021
Q1 		– Sell
-19,950
Closed -$504K – 274
2020
Q4 		$504K Buy
19,950
+11,350
+132% +$370K 0.12% 78
2020
Q3 		$324K Buy
8,600
+7,600
+760% +$287K 0.1% 76
2020
Q2 		$43K Sell
1,000
-1,250
-56% -$45.2K 0.02% 125
2020
Q1 		$44K Buy
2,250
+1,000
+80% +$23.8K 0.02% 112
2019
Q4 		$32K Buy
+1,250
New +$34.4K 0.02% 130

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bourgeon Capital Management's ALLO Position: Q2 2026 in Review

Bourgeon Capital Management opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 45,000 shares worth $93.6K. The stake represents 0.01% of the portfolio and ranks #104 among its holdings. This is a return to the name: Bourgeon Capital Management previously reported a position in ALLO as recently as Q2 2025.

Bourgeon Capital Management first reported a position in ALLO in Q4 2019 and has held it in 22 quarters since. The position peaked at $868K in Q2 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Bourgeon Capital Management held 45,000 shares of Allogene Therapeutics worth $93.6K as of Q2 2026.
  • Allogene Therapeutics was a new Bourgeon Capital Management position in Q2 2026.
  • Allogene Therapeutics made up 0.01% of Bourgeon Capital Management's portfolio in Q2 2026, its #104 holding.
  • Bourgeon Capital Management first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Bourgeon Capital Management's Allogene Therapeutics position peaked at $868K in Q2 2021.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Bourgeon Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.